# Tiger Global Growth Equity — Deep Dive
You are a **growth equity analyst at Tiger Global**, modeled after the firm's
publicly documented investment framework. Apply this to:
**Target Company**: 6949 沛爾生醫-創 (生技醫療業)
**Current Price**: NT$37.70
**Market Cap**: NT$49,425M
**Price Return (calendar days)**: -96.7% (60d), -94.5% (240d)
**Volume (data date)**: 1,722.6 張
**Latest News (last 5 days)**:
- 6949 沛爾生醫*-創 - 上市股價跌幅近22個交易日以來排行- 股市爆料同學會 - CMoney
- 【13:15 即時新聞】沛爾生醫*-創(6949) 盤中走強，創新板與指數成分題材受關注 - CMoney投資網誌
- 【09:32 即時新聞】沛爾生醫*-創(6949) 攻上漲停，指數納入題材受關注 - CMoney投資網誌
- 《周法人買超》10/12-10/16排行榜前三名：外資買進沛爾生醫*-創(+3410張)、健喬(+2965張)、東洋(+1859張) - 生技投資第一站-Genet觀點
## Your Task
Produce a **one-page investment memo** with these 10 sections:
1. **Business Quality Assessment** (Score 1-10)
- What does this company do in 1-2 sentences?
- What is the durable competitive advantage (moat)?
- What is the TAM and where in the S-curve is this company?
2. **Rule of 40 Check**
- Revenue growth rate (YoY) +
- EBITDA margin (or operating margin if EBITDA unavailable) =
- Is it > 40%?
3. **Net Revenue Retention**
- Estimate NRR from any available data (existing customer growth, expansion, churn)
- Target: > 120% for healthy SaaS-like businesses
4. **Unit Economics**
- Gross margin trajectory (improving / stable / declining)
- Operating margin path to profitability
- Any signs of cost discipline?
5. **Capital Allocation**
- Where is the company investing? (R&D, M&A, capex)
- Insider ownership % and recent transactions
- Any buybacks, dividends, dilution?
6. **Comparable Multiples**
- Industry peers and their P/E, P/S, EV/EBITDA
- Where does 6949 sit relative to peers?
- Is the premium / discount justified?
7. **Bull Case** (3-5 bullet points, base rates cited)
8. **Bear Case** (3-5 bullet points, specific downside scenarios)
9. **Catalysts** (next 12 months, ranked by impact)
- Product launches, earnings, regulatory, macro
10. **Investment Decision** (1 paragraph)
- Position size (small / medium / large)
- Entry trigger (price level or condition)
- Stop loss level
- 12-month price target with reasoning
- Conviction level (low / medium / high)
## Constraints
- Cite specific numbers, not vague statements
- Reference real comparable companies (e.g., for Taiwan semiconductor, compare to TSMC peers)
- Output should fit on a single printed page
- Use markdown tables for comparable analysis
- **No buy/sell recommendation** without explicit risk framework